Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of 2% Rebamipide (OPC-12759) Ophthalmic Solution in Healthy Adults
jRCT2080221632Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of rebamipide in dry eye syndrome (DED) (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Ocular safety and tolerability of 2% rebamipide ophthalmic solution. Started Oct 2011; status: completed.
02
Drugs
rebamipide
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2080221632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221632.